Trial Profile
A Long-Term, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Radiographic Study To Investigate The Safety And Efficacy Of Orally Administered SD-6010 In Subjects With Symptomatic Osteoarthritis Of The Knee
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Cindunistat (Primary)
- Indications Osteoarthritis
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms ITIC
- Sponsors Pfizer
- 23 Jan 2012 Actual patient number (5077) added as reported by ClinicalTrials.gov.
- 23 Jan 2012 Actual end date (1 Nov 2011 ) added as reported by ClinicalTrials.gov.
- 23 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.